{"id":"W3167182240","doi":"10.1038/s41467-021-23546-6","title":"Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"National Heart, Lung, and Blood Institute; Magyar Tudományos Akadémia; Innovációs és Technológiai Minisztérium; National Research, Development and Innovation Office; Magyarország Kormánya; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Semmelweis Egyetem; European Commission; Nemzeti Kutatási Fejlesztési és Innovációs Hivatal","keywords":"Lymphatic system; Lymphedema; Lymphangiogenesis; Nucleoside; Vascular endothelial growth factor C; Messenger RNA; Lymphatic Endothelium; Medicine; Cell biology; Biology; Internal medicine; Immunology; VEGF receptors; Vascular endothelial growth factor A; Vascular endothelial growth factor; Gene; Biochemistry; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001526687,0.0003287331,0.0002322048,0.000251914,0.0001149738,0.0001799074,0.0001393552,0.0002939958,0.0009424651],"category_scores_gemma":[0.0001315578,0.00007777945,0.0001788464,0.00009477227,0.0003187146,0.0002194634,0.0001221536,0.0006516324,0.0001320611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002193636,"about_ca_system_score_gemma":0.0002449791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005292398,"about_ca_topic_score_gemma":0.0007405084,"domain_scores_codex":[0.9998682,0.00002508312,0.000009936449,0.00002742678,0.00003743431,0.00003196449],"domain_scores_gemma":[0.9999062,0.00002174824,0.00003096049,0.00001009647,0.0000109137,0.00002003357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008136731,0.00004001479,0.00003992594,0.00003629884,0.000002237278,0.00003188074,0.000008790152,0.00006487087,0.998233,0.0001333945,0.00004385458,0.001284366],"study_design_scores_gemma":[0.00001946262,0.00057902,0.0004544147,0.000004776926,0.00001025591,0.0001140182,0.00001164084,0.0006540586,0.99669,0.00003447301,0.001424715,0.00000301973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861761,0.001748523,0.008689797,0.0002224602,0.0001737066,0.0001114795,0.0002023235,0.0002745029,0.002401112],"genre_scores_gemma":[0.9922034,0.001027117,0.003996564,0.00008424943,0.000029924,0.00006985829,0.0001856379,0.00003987343,0.002363297],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009424651,"threshold_uncertainty_score":0.003152847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03432543051118386,"score_gpt":0.3163444790360442,"score_spread":0.2820190485248604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}